内容紹介
An Assessment Tool for Chemotherapy-Induced Nausea and Vomiting and Intervention Outcomes
Summary
Chemotherapy-induced nausea and vomiting(CINV)is the most unpleasant side effect for patients receiving cancer chemotherapy. Moderately emetic anticancer drugs show a wide range of emetic frequencies, and the use or nonuse of antiemetics is optionally described without specifics. In the present study, we clarified the state of CINV presentation caused by moderately emetic anticancer drugs using the MASCC Antiemesis Tool, a nausea-and-vomiting evaluation tool developed by the Multinational Association of Supportive Care in Cancer(MASCC)for patients with colorectal cancer. Of the 32 subjects, 5(15.6%)had vomiting and 22(68.8%)experienced nausea. The timing of their occurrence and their nausea scores were accurately and easily clarified. This study's findings suggested that the current regimens need to be reviewed, particularly because all patients exhibited late nausea; therefore, we modified our antiemetic regimens through the Cancer Chemotherapy Regimen Review Board of this hospital. After the modification was introduced, significant improvement was seen in the control of both acute and late nausea/vomiting.
要旨
化学療法に伴う悪心・嘔吐(chemotherapy-induced nausea and vomiting: CINV)は,がん化学療法において患者が最も嫌う副作用である。また,中等度催吐性抗がん剤は催吐頻度が幅広くアプレピタント使用の有無はオプションとしてのみ記載され具体的な提示はない。そこで今回,大腸がん症例においてMaltinational Association of Supportive Care in Cancer(MASCC)が開発した悪心・嘔吐評価ツールであるMASCC Antiemesis Tool(MAT)を用いて中等度催吐性抗がん剤のCINVの発現状況を明らかにした。その結果,5/32例(15.6%)に嘔吐,22/32例(68.8%)に悪心が出現し,その発現時期および悪心スコアを正確かつ簡便に知ることができた。本研究では,特に遅発性悪心が全例にみられることから現在のレジメンを見直す必要があることが示唆され,当院のがん化学療法レジメン審査委員会をとおして制吐剤のレジメン変更を行った。制吐剤変更後は,有意に急性・遅発性の悪心・嘔吐ともに改善が認められた。
目次
Summary
Chemotherapy-induced nausea and vomiting(CINV)is the most unpleasant side effect for patients receiving cancer chemotherapy. Moderately emetic anticancer drugs show a wide range of emetic frequencies, and the use or nonuse of antiemetics is optionally described without specifics. In the present study, we clarified the state of CINV presentation caused by moderately emetic anticancer drugs using the MASCC Antiemesis Tool, a nausea-and-vomiting evaluation tool developed by the Multinational Association of Supportive Care in Cancer(MASCC)for patients with colorectal cancer. Of the 32 subjects, 5(15.6%)had vomiting and 22(68.8%)experienced nausea. The timing of their occurrence and their nausea scores were accurately and easily clarified. This study's findings suggested that the current regimens need to be reviewed, particularly because all patients exhibited late nausea; therefore, we modified our antiemetic regimens through the Cancer Chemotherapy Regimen Review Board of this hospital. After the modification was introduced, significant improvement was seen in the control of both acute and late nausea/vomiting.
要旨
化学療法に伴う悪心・嘔吐(chemotherapy-induced nausea and vomiting: CINV)は,がん化学療法において患者が最も嫌う副作用である。また,中等度催吐性抗がん剤は催吐頻度が幅広くアプレピタント使用の有無はオプションとしてのみ記載され具体的な提示はない。そこで今回,大腸がん症例においてMaltinational Association of Supportive Care in Cancer(MASCC)が開発した悪心・嘔吐評価ツールであるMASCC Antiemesis Tool(MAT)を用いて中等度催吐性抗がん剤のCINVの発現状況を明らかにした。その結果,5/32例(15.6%)に嘔吐,22/32例(68.8%)に悪心が出現し,その発現時期および悪心スコアを正確かつ簡便に知ることができた。本研究では,特に遅発性悪心が全例にみられることから現在のレジメンを見直す必要があることが示唆され,当院のがん化学療法レジメン審査委員会をとおして制吐剤のレジメン変更を行った。制吐剤変更後は,有意に急性・遅発性の悪心・嘔吐ともに改善が認められた。